الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 200 |  |  |
| | | from | 200 | | |
Abstract
This work is a trial to postulate the pretreatment effects of a newly introduced selective COX-2 inhibitor namely
{Rofecoxib} versus a non-selective COX inhibitor namely
{Indomethacin} on plasma insulin levels and pancreatic free hydroxyl radicals as well as histopathological changes of islets beta cells in an experimental model of islet beta cell dysfunction in rats by streptozotocin.
Four groups of white male albino rats were used, each comprising twenty rats. 151 group served as control and the remaining three groups were treated with the test drugs and streptozotocin..
Experiments were done on streptozotocin treated rats to study the prophylactic effects of Rofecoxib versus Indomethacin on:
1). Plasma insulin levels both basal and half an hour after glucose load.
2). Histopathological changes of islet beta cells m different The results revealed the following:
Intraperitoneal injection of streptozotocin m normal rats produced:
a) Significant reduction in plasma insulin levels both basal and
half an hour after glucose load by mean percentage values of
65.44%(P<0.001) and 74.60%(P<O.OOl)respectively.
b) Severe damage in the pancreatic beta cells with marked depletion of insulin secretory granules.
c) Significant increase in pancreatic MDA level by a mean percentage value of 1 15.0 I% (P<O.OOO1).
Pretreatment with Rofecoxib (2.5mg/kg/day) before streptozotocin produced:
a) Insignificant reduction in plasma insulin levels both basal and half an hour after glucose load by mean percentage values of
24.79% (P>0.05) & 36.12% (P>0.05) respectively.
b) Unremarkable histopathological changes. The pancreatic beta cells appeared quite normal with preserved insulin secrerory granules.
c) Insignificant mcrease 111 pancreatic MDA level by mean percentage value of 26.55% (P>0.05).